Dermata Therapeutics, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Equity Securities (Details Narrative)

Equity Securities (Details Narrative) - USD ($)						1 Months Ended			3 Months Ended		12 Months Ended
Equity Securities (Details Narrative) - USD ($)	Mar. 27, 2025	Jan. 21, 2025	Sep. 17, 2024	Aug. 02, 2024	May 21, 2024	Sep. 30, 2024	Jul. 31, 2024	Jun. 30, 2024	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024	Sep. 16, 2024	Aug. 01, 2024	May 17, 2024	Nov. 30, 2023	May 26, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net proceeds from exercise of warrants									$ 977
Shares held in abeyance									4,232,470
Offering expenses									$ 50,495
Warrants outstanding									12,389,769		5,068,455
Net proceeds from offering									$ 8,541,282
Preferred stock, shares authorized									10,000,000		10,000,000
Preferred stock, par value									$ 0.0001		$ 0.0001
Preferred stock, shares issued									0		0
Preferred stock, shares outstanding									0		0
Share price per share									$ 1.08
Intrinsic value of warrants outstanding									$ 0
January 2025 PIPE [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net cash proceeds		$ 2,300,000
Offering expenses		300,000
January 2025 PIPE [Member] \| Company Insiders [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Aggregate purchase price		$ 1,550,000
September 2024 PIPE [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net cash proceeds			$ 3,100,000
Offering expenses			$ 400,000
Pre-Funded Warrants [Member] \| January 2025 PIPE [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise price		$ 0.001
Warrants to purchase common stock		72,468
Warrants outstanding									0
Pre-Funded Warrants [Member] \| September 2024 PIPE [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise price			$ 0.001
Warrants to purchase common stock			1,912,569
Warrants outstanding									0		905,000
PIPE Warrants [Member] \| January 2025 PIPE [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise price		$ 1.27
Warrants to purchase common stock		2,007,880
Common stock issuable upon exercise of warrants		2,007,880
PIPE Warrants [Member] \| January 2025 PIPE [Member] \| Company Insiders [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase common stock		1,220,476
PIPE Warrants [Member] \| September 2024 PIPE [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise price			$ 1.58
Series A Warrants [Member] \| September 2024 PIPE [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase common stock			1,912,569
Common stock issuable upon exercise of warrants			1,912,569
Series B Warrants [Member] \| September 2024 PIPE [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase common stock			1,912,569
Common stock issuable upon exercise of warrants			1,912,569
May 2024 Series A Common Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise price									$ 4.91
Warrants outstanding									23,340		601,174
May 2024 Series B Common Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise price									$ 4.91
Warrants outstanding											431,498
March 2025 Warrant Inducement Series A Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise price									$ 1.284
Warrants outstanding									4,980,806
March 2025 Warrant Inducement Series B Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise price									$ 1.284
Warrants outstanding									4,688,134
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares of common stock issued									602,000
Shares held in abeyance									4,232,470
Common Stock [Member] \| January 2025 PIPE [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares sold		1,935,412
Common Stock [Member] \| January 2025 PIPE [Member] \| Company Insiders [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares sold		1,220,476
Common Stock [Member] \| September 2024 PIPE [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares sold			1,912,569
Common Stock [Member] \| ATM Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares sold						194,218	355,806	1,157,761			550,024
Offering expenses							$ 513
Fixed commission rate on gross sales price of common stock								3.00%
Gross proceeds from offering						$ 504,894	$ 1,157,248
Increase in maximum aggregate offering amount of common stock issuable				$ 505,000
Maximum aggregate offering amount of common stock issuable				$ 1,662,761									$ 1,157,761
Net proceeds from offering											$ 1,500,000
March 2025 Inducement Letter Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise price												$ 1.58		$ 4.91
Net proceeds from exercise of warrants	$ 5,800,000
Shares of common stock issued									602,000
Shares held in abeyance									4,232,470
March 2025 Inducement Letter Agreement [Member] \| Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise price	$ 1.284
Net proceeds from exercise of warrants	$ 5,800,000
Warrants to purchase common stock	4,834,470
Equity issuance costs	$ 4,900,000
March 2025 Inducement Letter Agreement [Member] \| New Series A Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase common stock	4,980,806
March 2025 Inducement Letter Agreement [Member] \| New Series B Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase common stock	4,688,134
March 2025 Inducement Letter Agreement [Member] \| March 2025 Warrant Inducement Series A Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise price	$ 1.284
Warrants to purchase common stock	4,980,806
March 2025 Inducement Letter Agreement [Member] \| March 2025 Warrant Inducement Series B Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise price	$ 1.284
Warrants to purchase common stock	4,688,134
March 2025 Inducement Letter Agreement [Member] \| Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase common stock	4,834,470
May 2024 Inducement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares held in abeyance							267,000
May 2024 Inducement [Member] \| Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise price					$ 5.16										$ 9.7665	$ 32.40
Net proceeds from exercise of warrants					$ 2,300,000
Warrants to purchase common stock					516,336
Equity issuance costs					$ 1,500,000
May 2024 Inducement [Member] \| May 2024 Series A Common Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise price					$ 4.91
Warrants to purchase common stock					601,174
May 2024 Inducement [Member] \| May 2024 Series B Common Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise price					$ 4.91
Warrants to purchase common stock					431,498